HC Wainwright & Co. Reiterates Buy on Replimune Group, Raises Price Target to $50
HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) with a Buy and raises the price target from $48 to $50.
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.
BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70
BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.
Reported Late Thursday, Replimune Announces Pricing Of $225M Public Offering Of 5,374,486 Shares Of Common Stock At A Price Of $23.50/Share
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering
Analyst Ratings for Replimune Group
Replimune Group (NASDAQ:REPL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $30 to $34.
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint.
Replimune Enters Clinical Collaboration Agreement With Roche For Development Of RP3 In Colorectal Cancer And Hepatocellular Carcinoma
P3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $30
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $37 to $30.
Piper Sandler Maintains Overweight on Replimune Group, Lowers Price Target to $43
Piper Sandler analyst Do Kim maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $44 to $43.